These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36941533)

  • 1. Both perimenstrual and nonperimenstrual migraine days respond to anti-calcitonin gene-related peptide (receptor) antibodies.
    Verhagen IE; de Vries Lentsch S; van der Arend BWH; le Cessie S; MaassenVanDenBrink A; Terwindt GM
    Eur J Neurol; 2023 Jul; 30(7):2117-2121. PubMed ID: 36941533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of erenumab in women with a history of menstrual migraine.
    Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
    J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y; Huang ZL
    Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K; Vandenbussche N; Goadsby PJ
    Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary.
    van Casteren DS; Verhagen IE; van der Arend BWH; van Zwet EW; MaassenVanDenBrink A; Terwindt GM
    Neurology; 2021 Oct; 97(17):e1661-e1671. PubMed ID: 34493613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-calcitonin generelated peptide (CGRP) therapies for migraine].
    Moisset X; Demarquay G
    Rev Prat; 2023 Feb; 73(2):123-126. PubMed ID: 36916250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Iannone LF; De Cesaris F; Ferrari A; Benemei S; Fattori D; Chiarugi A
    Cephalalgia; 2022 Nov; 42(13):1323-1330. PubMed ID: 35775208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
    Henson B; Hollingsworth H; Nevois E; Herndon C
    J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
    Varnado OJ; Hoyt M; Ye W; Nicholson R
    Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study.
    de Vries Lentsch S; van der Arend BWH; Maassen VanDenBrink A; Terwindt GM
    Neurology; 2022 Oct; 99(17):e1897-e1904. PubMed ID: 36195452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine.
    de Vries Lentsch S; van der Arend BWH; de Boer I; van Zwet EW; MaassenVanDenBrink A; Terwindt GM
    Eur J Neurol; 2024 Feb; 31(2):e16106. PubMed ID: 37847221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
    Arca K; Reynolds J; Sands KA; Shiue HJ
    Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
    Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
    Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.